Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inmune Bio Inc (NQ: INMB )

6.040 +0.190 (+3.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inmune Bio Inc

< Previous 1 2 3 4 5 Next >
INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio's Earnings Outlook
Via Benzinga
The 7 Best Biotech Stocks for Personalized Medicine Investors
Personalized Medicine Stocks Promise to Make Healthcare More Individualized with therapeutics based on individual genetics. 
Via InvestorPlace
INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Earnings Perspective: Return On Capital Employed
Via Benzinga
Earnings Preview: INmune Bio
Via Benzinga
What to Know About the Future of Cancer Treatment
Via StatePoint Media
XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio's INKmune Shows Positive Efficacy In Multiple Cancer Cell Lines
Via Benzinga
INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2
From INmune Bio, Inc.
Via GlobeNewswire
Dow Jumps 250 Points; US Jobless Claims Increase Last Week
U.S. stocks traded higher this morning, with the Dow Jones jumping around 250 points on Thursday. The Dow traded up 0.75% to 34,204.99 while the NASDAQ rose 1.15% to 12,047.28. The S&P 500 also rose,... 
Via Benzinga
Nasdaq Tumbles 150 Points; Crude Oil Up 1.5%
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping over 150 points on Wednesday. The Dow traded down 0.27% to 34,063.42 while the NASDAQ fell 1.33% to 11,952.51. The... 
Via Benzinga
INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom
From INmune Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune
From INmune Bio, Inc.
Via GlobeNewswire
Recap: INmune Bio Q2 Earnings
INmune Bio (NASDAQ:INMB) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings INmune Bio beat estimated... 
Via Benzinga
71 Biggest Movers From Yesterday
Gainers CynergisTek, Inc. (NYSE: CTEK) shares surged 100% to close at $1.18 on Tuesday after the company entered into a definitive agreement to be acquired by Clearwater Compliance for roughly $17.7... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers CynergisTek, Inc. (NYSE: CTEK) jumped 100% to $1.18 after the company entered into a definitive agreement to be acquired by Clearwater Compliance for roughly $17.7 million. 
Via Benzinga
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.